Fig. 7
FerOX uptake preserves PBMC proliferation in vitro and ex vivo. A Proliferation index of PBMC collected from healthy donors, labelled with CFSE 1 μM and stimulated with ConA (5 μg/mL) after 3 h in vitro treatment with DOX, Myocet or FerOX 5 μM to simulate what occurs during the infusion time of DOX NAC. Proliferation index has been calculated using the software FlowJo (version 10). Statistical significance: *p < 0.05 (paired t-test) (n = 3). B Proliferation index of CD4+ T cells collected from healthy donors, labelled with CFSE 1 μM and stimulated with ConA (5 μg/mL) after 3 h in vitro treatment with DOX, Myocet or FerOX 5 μM calculated using the software FlowJo (version 10). Statistical significance: *p < 0.05 (paired t-test) (n = 3). C Proliferation index of CD8+ T cells collected from healthy donors, labelled with CFSE 1 μM and stimulated with ConA (5 μg/mL) after 3 h in vitro treatment with DOX, Myocet or FerOX 5 μM calculated using the software FlowJo (version 10). Statistical significance: *p < 0.05; **p < 0.01 (paired t-test) (n = 3). D Proliferation index of PBMC collected from BC patients before and after DOX NAC, labelled with CFSE 1 μM and stimulated with ConA (5 μg/mL). PBMC collected from BC patients before DOX NAC have been treated in vitro for 3 h with DOX, Myocet or FerOX 5 μM, in order to simulate chemotherapy. Proliferation indexes have been calculated using the software FlowJo (version 10). Statistical significance: *p < 0.05; **p < 0.01 (paired t-test) (n = 3). E Proliferation index of CD4+ T cells collected from BC patients before and after DOX NAC, labelled with CFSE 1 μM and stimulated with ConA (5 μg/mL). PBMC collected from BC patients before DOX NAC have been treated in vitro for 3 h with DOX, Myocet or FerOX 5 μM, in order to simulate chemotherapy. Proliferation indexes have been calculated using the software FlowJo (version 10). Statistical significance: *p < 0.05 (paired t-test) (n = 3). F Proliferation index of CD8+ T cells collected from BC patients before and after DOX NAC, labelled with CFSE 1 μM and stimulated with ConA (5 μg/mL). PBMC collected from BC patients before DOX NAC have been treated in vitro for 3 h with DOX, Myocet or FerOX 5 μM, in order to simulate chemotherapy. Proliferation indexes have been calculated using the software FlowJo (version 10). Statistical significance: *p < 0.05; **p < 0.01 (paired t-test) (n = 3)